Measuring Myelin Repair and Axonal Loss with Diffusion Tensor Imaging

R.J. Fox, T. Cronin, J. Lin, X. Wang, K. Sakaie, D. Ontaneda, S.Y. Mahmoud, M.J. Lowe and M.D. Phillips

*AJNR Am J Neuroradiol* 2011, 32 (1) 85-91
doi: https://doi.org/10.3174/ajnr.A2238
http://www.ajnr.org/content/32/1/85
Measuring Myelin Repair and Axonal Loss with Diffusion Tensor Imaging

BACKGROUND AND PURPOSE: DTI is an MR imaging measure of brain tissue integrity and provides an attractive metric for use in neuroprotection clinical trials. The purpose of our study was to use DTI to evaluate the longitudinal changes in brain tissue integrity in a group of patients with MS.

MATERIALS AND METHODS: Twenty-one patients with MS starting natalizumab were imaged serially for 12 months. Gadolinium-enhancing lesions and 20 regions of interest from normal-appearing white and gray matter brain tissue were followed longitudinally. Average values within each region of interest were derived for FA, λ₁, λ₂, and MD. New T1 black holes were identified at 12 months. Analysis was performed by using mixed-model regression analysis with slope (ie, DTI change per month) as the dependent variable.

RESULTS: During 1 year, FA increased in gadolinium-enhancing lesions but decreased in NABT (P < .0001 for both). Changes in FA within gadolinium-enhancing lesions were driven by decreased λ₁ (P < .001), and within NABT, by decreased λ₂ (P < .0001). A higher λ₁ within gadolinium-enhancing lesions at baseline predicted conversion to T1 black holes at 12 months. MD was unchanged in both gadolinium-enhancing lesions and NABT.

CONCLUSIONS: We observed changes in DTI measures during 1 year in both gadolinium-enhancing lesions and NABT. The DTI results may represent possible remyelination within acute lesions and chronic axonal degeneration in NAWM. These results support the use of DTI as a measure of tissue integrity for studies of neuroprotective therapies.

ABBREVIATIONS: AFNI = Analysis of Functional NeuroImages; DTI = diffusion tensor imaging; EAE = experimental allergic encephalomyelitis; FA = fractional anisotropy; λ₁ = axial diffusivity; λ₂ = radial or transverse diffusivity; MD = mean diffusivity; MPRAGE = magnetization-prepared rapid acquisition of gradient echo; MS = multiple sclerosis; NABT = normal-appearing brain tissue; NAWM = normal-appearing white matter; n.s. = not significant; ROI = region of interest

MS is a chronic demyelinating disease of the central nervous system. Conventional MR imaging readily identifies the classic hallmarks of MS in white matter yet has distinct disadvantages.¹ Focal lesions identify areas of active inflammation and tissue injury but do not characterize the degree of tissue injury. Despite an absence of new lesions in patients with progressive MS, chronic progressive disability is observed for many years. Altogether, conventional imaging is a poor measure of the degree of acute injury, later recovery, and chronic degeneration. More advanced imaging modalities are needed to characterize the degree of tissue injury and its response to therapies more accurately.

DTI is a quantitative MR imaging technique that measures the 3D diffusion of water molecules within tissue through the application of multiple diffusion gradients.² The power of diffusion techniques comes from measurement of molecular probing of tissue structures by water molecules at a microscopic scale well beyond the typical MR imaging resolution. By measuring the interaction of water molecules with cell membranes, myelin sheaths, and macromolecules, tissue integrity can be inferred.³ Tissue has physical structures that limit diffusion in different directions, so diffusion is typically described as a 3D ellipsoid through a 3 × 3 matrix. In nervous tissue, the largest (or primary) ellipsoid eigenvector represents diffusion along the length of a fiber tract and so is referred to as the λ₁. The other shorter 2 ellipsoid eigenvectors, when averaged together, are called λ₂. Clinical and pathologic studies have found that λ₁ tends to reflect axonal integrity, whereas λ₂ corresponds more closely to myelin integrity.⁴⁻⁸ Animal and human studies suggest that λ₁ and λ₂ are approximate measures of axonal and myelin integrity, particularly in acute injury.

Diffusion ellipsoids in highly organized fiber tracts (eg, pyramidal tracts and the corpus callosum) are very elongated. The absence of fiber tracts in gray matter makes diffusion ellipsoids less elongated, though gray matter still demonstrates some anisotropy. FA is a common metric to describe the degree of diffusion directionality or elongation. A high FA within a single voxel would signify that diffusion occurs predominantly along a single axis. A low FA would signify that diffusion occurs along all 3 cardinal axes. An overall measure
of diffusion magnitude is described by MD, which ignores anisotropy and simply describes the overall magnitude of diffusion.

Given the limited dynamic range of conventional imaging to characterize tissue integrity, DTI is an attractive alternative to conventional imaging for measuring tissue integrity in longitudinal MS studies and the potential impact of therapy. Although several studies have correlated DTI measures with functional performance, little is known about how DTI measures tissue recovery and later degeneration. Similarly, to our knowledge, few studies have evaluated the changes in brain tissue during treatment with natalizumab, and no studies have evaluated patients with MS after starting immunomodulating therapy. In this study, we evaluated the longitudinal change in DTI measures within focal brain regions of patients with MS starting highly effective anti-inflammatory therapy. Specifically, we evaluated the ability of DTI of the brain to characterize changes following acute inflammatory injury and chronic changes in NABT. We hypothesized that longitudinal DTI imaging will measure changes in brain tissue integrity in both gadolinium-enhancing lesions and NABT.

**Materials and Methods**

**Participants**

After obtaining local institutional review board approval, we enrolled 22 patients with MS into a longitudinal observational DTI study starting treatment with natalizumab, with baseline MR imaging immediately before the first natalizumab infusion. Patients were enrolled sequentially into this natural history study from an academic specialty clinical center. Inclusion criteria were clinically definite MS by the Revised McDonald Diagnostic Criteria, age >18 years, and ability to provide informed consent. Exclusion criteria were clinical relapse or steroid treatment in the previous 8 weeks (to minimize the potential confounding of corticosteroids), pregnancy, and contraindications to MR imaging, such as severe claustrophobia and implanted devices, such as neurostimulators, pacemakers, and so forth. Patients with MS started natalizumab for clinical indications, according to the US Food and Drug Administration label. Because this was a small pilot study funded by the National Institutes of Health and National Multiple Sclerosis Society, no untreated controls were studied. Written informed consent was obtained from all participants. One patient discontinued imaging follow-up after only 2 months and was removed from the data analysis.

**MR Imaging Protocol**

Imaging was performed on a 3T Trio scanner (Siemens Medical Systems, Erlangen, Germany). Diffusion-weighted imaging used T1 noncollinear diffusion-weighting gradients (2.5 × 2.5 × 2.5 mm voxels, b=2000 s/mm², 8 b=0 acquisitions, 256 × 256 mm FOV, 102 × 102 matrix, forty-eight 2.5-mm-thick sections, TE/TR = 95/7300 ms). Anatomic imaging was performed for lesion detection and coregistration: 3D MPRAGE (256 × 256 mm FOV, 256 × 128 matrix, one hundred twenty 1.2-mm-thick sections, TE/TR = 1.71/1900 ms), proton attenuation/T2-weighted (230 × 230 mm FOV, 320 × 320 matrix, forty-eight 3-mm sections, TE1/TE2/TR = 20/91/3600 ms), and T1 fast low-angle shot (230 × 230 mm FOV, 320 × 320 matrix, forty-eight 3-mm sections, TE/TR = 2.46/300 ms, flip angle = 75°) postgadolinium (0.1 mmol/kg). Total time of each DTI scan was 10 minutes, 40 seconds, for a total scanning time of 47 minutes, 14 seconds. Conventional and DTI images were assessed within a few days of acquisition for quality, and patients returned for repeat acquisition if significant artifacts (ie, spike artifacts, motion) were observed.

**Image Analysis**

At baseline, all gadolinium-enhancing lesions and 20 regions of interest from NABT (Fig 1) were drawn on each subject by using AFNI. For gadolinium-enhancing lesions, regions of interest were drawn over the gadolinium-enhancing region of the lesion on postgadolinium T1-weighted images. For NABT, regions of interest were drawn onto the FA maps to improve the accuracy of longitudinal coregistration. NABT regions of interest were chosen to represent varied white matter and deep gray matter regions. NABT regions of interest were not drawn on areas that showed abnormal signal intensity on either T1-weighted or T2-weighted images at baseline or any follow-up scan. Tissue immediately adjacent to CSF was not included in either gadolinium-enhanced lesions or NABT because of possible later coregistration errors that may include CSF. Regions of interest were followed longitudinally by coregistration of anatomic T1-MPRAGE images acquired at months 1, 2, 6, and 12 to the T1-MPRAGE image acquired at baseline by using Functional MRI of the Brain Software Library. Regions of interest were inspected through AFNI at each time point to confirm the accuracy of coregistration and were adjusted when necessary. The reproducibility of these measures in NABT by using this coregistration technique was shown in a previous study, with a median coefficient of variation over 3 annual scans of 9.59% for FA, 2.21% for apparent diffusion coefficient (comparable with MD), 3.70% for λ₁, and 4.19% for λ₂. Enhancing lesions at baseline were classified at 12 months as either isointense or hypointense (black holes) on T1 images. Isointensity was defined as an inability to visualize any portion of the lesion on nonenhanced T1 images. T1-hole designation at 12 months was then confirmed by a second investigator, and both investigators were blinded to DTI measures. Average values within each region of interest were derived for FA, λ₂, λ₀, and MD. For descriptive purposes, QBrain Version 1.1.20.0 (Medis Medical Imaging Systems, Leiden, the Netherlands) was used to measure T2 lesion volumes.

**Statistical Analysis**

Longitudinal analysis and group comparisons were performed by using mixed-model analysis, with slope (ie, DTI change per month) as the dependent variable. The ability of baseline DTI measures within gadolinium-enhancing lesions to predict T1 black holes at 12 months was evaluated by using either a Satterthwaite or pooled t test, depending on equality of variances for each DTI measure. All assumptions of each statistical model were met. Because of multiple comparisons, significance was set at P < .01. Statistical analysis was performed by 1 coauthor (X.W.). Because this was an exploratory study and few longitudinal DTI data are available in patients with MS, no formal power calculations were performed.

**Results**

A description of the 21 patients with MS is found in the Table. As a group, these patients are similar to those in previous natalizumab clinical trials (Miller, Polman, Rudick). At baseline, 11 of 21 patients demonstrated a total of 60 (median = 5) enhancing lesions. At 12 months, 26 (43%) of those enhancing lesions were T1 black holes. There was 85% compliance with natalizumab therapy.
DTI Changes Following Acute Inflammatory Injury

During 1 year, FA increased in gadolinium-enhancing lesions \((+2.10/\text{month}, P < .0001; \text{Fig 2})\). This increase was most prominent during the first 2 months and then became more gradual. Changes in FA within gadolinium-enhancing lesions were driven by decreased \(\lambda_{\perp} (-1.95 \times 10^{-6} \text{ mm}^2/\text{s}/\text{month}, P < .003)\). MD was unchanged in gadolinium-enhancing lesions \((P = \text{n.s., data not shown}).\)

Higher \(\lambda_{\perp}\) within gadolinium-enhancing lesions at baseline predicted conversion to T1 black holes at 12 months \((P = .0007)\). FA at baseline showed a trend for predicting T1 black holes at 12 months \((P = .011)\). Changes in DTI measures during 1 year did not differ between enhancing lesions that became T1 black holes and lesions that did not become T1 black holes (Fig 3).

DTI Changes in NABT

During 1 year, FA decreased in NABT \((-1.02/\text{month}, P < .0001; \text{Fig 4})\). This decrease was gradual during the entire 12-month follow-up. Changes in FA within NABT were driven by decreased \(\lambda_{\parallel} (-1.92 \times 10^{-6} \text{ mm}^2/\text{s}/\text{month}, P < .0001)\). MD was unchanged in NABT \((P = \text{n.s., data not shown}).\)

Discussion

We used longitudinal evaluation of patients with MS starting anti-inflammatory therapy to evaluate the ability of DTI to characterize changes within areas of focal inflammatory injury. Within gadolinium-enhancing lesions, we observed increased FA and decreased \(\lambda_{\perp}\) during the first 2 months. Remyelination is well-known to occur following acute demyelination injury,\(^{15-17}\) and the reduction in \(\lambda_{\perp}\) may represent an imaging correlate of remyelination. Experimental animal studies have suggested that \(\lambda_{\perp}\) is a somewhat specific measure of myelin integrity. Demyelination without axonal injury is induced in cuprizone-treated mice, and changes in \(\lambda_{\perp}\) paralleled pathologically confirmed demyelination and remyelination.\(^{18}\) DTI studies in shiverer mice (who have congenital dysmyelination with intact axons) found increased \(\lambda_{\perp}\) but normal \(\lambda_{\parallel}\).\(^{9}\) In the EAE mouse model, focal regions of myelin loss are associated with decreased \(\lambda_{\perp}^{4}\). Animal ischemia studies also found increased \(\lambda_{\perp}\) but no change \(\lambda_{\parallel}\) and histopathology showed reduced myelination.\(^{19}\) DTI studies from a mouse traumatic brain injury model found reduced FA
and $\lambda_0$ which corresponded to increased staining for amyloid precursor protein and neurofilament, both indicators of axonal injury.\textsuperscript{20} Altogether, these animal imaging studies suggest that the changes in $\lambda_0$ we observed within gadolinium-enhancing lesions possibly represent remyelination.

An alternative pathologic explanation for the longitudinal increased FA within gadolinium-enhancing lesions is resolution of edema and inflammatory infiltrates. However, DTI studies from other cerebral edema models suggest that there is little contribution of resolving edema to our DTI observations. Cerebral edema from hepatic encephalopathy is associated with increased MD and variable changes in FA.\textsuperscript{21,22} After lactulose therapy for hepatic encephalopathy, MD decreased while FA did not change.\textsuperscript{22} Peritumoral edema shows both a decrease in FA and an increase in apparent diffusion coefficient (which is comparable with MD).\textsuperscript{23,24} Individual eigenvalue analysis of peritumoral edema showed increase in both $\lambda_\perp$ and $\lambda_0$. In contrast, we observed no change in either $\lambda_\parallel$ or $\lambda_0$. Furthermore, we observed a change in $\lambda_\perp$ alone, with no change in $\lambda_\parallel$. Although the resolution of gadolinium-enhancing lesions likely involves some resolving edema, comparison of our DTI observations with those from hepatic en-
Chronic T1 hypointensities (T1 black holes) are associated with severe tissue damage, as measured by axonal loss, axonal swelling, and demyelination. To date, no published studies have evaluated DTI predictors of conversion from gadolinium-enhancing lesions to T1 black holes. In our study, approximately half of the gadolinium-enhancing lesions developed into T1 black holes by 12 months. $\lambda_1$ within gadolinium-enhancing lesions at baseline predicted evolution into T1 black holes, and a trend was observed with FA. In contrast, we observed no difference in change in DTI measures during 1 year of follow-up between gadolinium-enhancing lesions that became T1 black holes and those that did not. These observations suggest that evolution of gadolinium-enhancing lesions into T1 black holes is influenced predominantly by the degree of initial injury and not the amount of later recovery. These observations also add to the accumulating evidence that DTI is a quantitative measure of the degree of brain tissue injury.

We also applied DTI to study changes in NABT with time during MS therapy. This longitudinal analysis showed gradual decline in FA during 1 year of follow-up. In contrast to enhancing lesions, this decline was driven by a decrease in $\lambda_1$, with no significant change in $\lambda_2$. Animal studies of inflammatory injury found a relative specificity of $\lambda_1$ to represent axonal injury. DTI studies of the spinal cord of mice with EAE showed decreased $\lambda_1$ throughout the cord, which correlated with increased staining of antibodies against the axonal-relevant $\beta$-amyloid precursor protein. Retinal ischemia causes wallerian degeneration of the optic nerve, leaving myelin intact for a period of time. Three days after induction of retinal ischemia, DTI of the optic nerve shows decreased $\lambda_1$ with no change in $\lambda_2$. Subsequent pathology confirmed axonal degeneration without demyelination. A study of patients with corpus callosotomy found an early decrease in $\lambda_1$ in the white matter adjacent to the surgery, which was followed by a later decline in $\lambda_2$. This imaging time course parallels the wallerian degeneration following axonotomy, with distal axonal loss first, followed later by myelin loss.

These animal studies suggest that our observed decline in $\lambda_1$ represents an ongoing degenerative process outside of demyelinating lesions, which preferentially affects axonal integrity. The changes we observed continued despite anti-inflammatory therapy. Continued degeneration in NABT was also observed as accelerated brain atrophy in natalizumab-treated patients compared with healthy controls. Our studies suggest that a similar process driven by axonal loss may be occurring in the NABT in patients with MS, even in the absence of active inflammation as measured by clinical relapses and gadolinium-enhancing lesions. There was no change with time in MD within NABT, which suggests that changes in FA and $\lambda_1$ were not secondary to resolution of generalized edema.

There are few other longitudinal DTI studies in MS, and no studies have evaluated patients after starting a specific therapy. One 18-month study of untreated patients with MS found increased MD and decreased FA with time in chronic MS lesions. MD also increased in normal-appearing gray matter, but not NAWM. Another study of mostly patients with progressive MS found that MD (but not FA) increased during 2.4 years in NAWM. We studied patients at an earlier stage of disease and after starting anti-inflammatory therapy, so our observations more accurately characterize a stage of disease that has greater potential for tissue recovery. In addition, we were able to characterize the continued neurodegeneration in NABT, despite cessation of active inflammation. Finally, compared with our study using 71 diffusion gradients, both previous DTI studies used an 8-direction pulse sequence. It has been shown that at least 20 and 30 directions are necessary for robust determination of anisotropy and mean diffusivity, respectively.
In an open-label study with no formal control group, it may be difficult for our data to differentiate the effect of anti-inflammatory therapy from the natural course of MS. Gadolinium enhancement always resolves, so the increase in FA may be secondary simply to the natural resolution of inflammation in this disease. DTI measures vary from 1 brain region to another and from 1 patient to another, making comparison studies difficult to interpret. Our longitudinal comparison of the same brain regions within the same patients minimized this problem. Furthermore, there is no pathologic data comparing treated and untreated patients with MS, making it difficult to extrapolate imaging data to pathologic changes. Future studies comparing treated and untreated patients are needed to identify the effects of MS therapy on DTI measures of tissue integrity more clearly. This study enrolled patients with MS with variable disease duration and different prior MS therapies, irrespective of other comorbid conditions. Although this process introduces variability in the dataset, it also allows greater generalization of this dataset to general clinical practice and future clinical trials. Indeed, the subjects are representative of both the general MS population and those studied in the major natalizumab clinical trials, making these observations widely applicable to the general MS patient population.

It is well-established that natalizumab therapy reduces new lesions as measured by conventional imaging, but less known is the impact of any immunosuppressive therapy on advanced imaging measures. The rate of progressive brain atrophy is slower in patients treated with natalizumab, but only in the second year of therapy. Natalizumab therapy was associated with a reduction in conversion of gadolinium-enhancing lesions into T1 black holes. No studies have evaluated the potential impact of natalizumab therapy on advanced imaging measures, such as DTI. Natalizumab prevents leukocyte adhesion to the capillary endothelial surface, thereby reducing leukocyte transmigration into the central nervous system. Natalizumab is associated with a rapid and robust reduction in the development of new gadolinium-enhancing lesions, which is expected to create a less inflammatory environment, thus allowing more effective repair. Furthermore, enhancing lesions in patients started on natalizumab are less likely to later convert to T1 black holes. These observations suggest that natalizumab therapy may have a positive impact on tissue integrity, even in regions with active inflammation.

Our observation suggests that during treatment with natalizumab, there is tissue recovery in areas of active inflammation, as measured by increased FA and reduced AD. Perhaps more important, we observed continued decline in FA and AD within NABT, despite treatment with a highly effective anti-inflammatory therapy. These observations add further evidence to the pathophysiologic separation between inflammation and degeneration. Additional studies are needed to compare our observations in natalizumab-treated patients with MS with untreated patients with MS.

Our results imply that DTI may provide pathology-specific insights into MS, because FA was driven by different eigenvectors in gadolinium enhancing lesions and NABT. If axial and radial diffusion indeed are relatively specific for axonal injury and demyelination, respectively, then DTI may be a useful biomarker of tissue recovery and later degeneration. Additionally, this study demonstrates that DTI is a dynamic measure of tissue integrity, with the ability to measure both short-term tissue recovery and long-term degeneration. These observations suggest that DTI may be a useful metric of therapeutic trials of tissue recovery and antidegeneration. These studies should target FA and individual diffusivities (AD for tissue recovery and AD for antidegeneration) instead of MD, because these appear to be more dynamic metrics with time.

Conclusions

We observed changes in DTI measures during 1 year in both gadolinium-enhancing lesions and NABT. The DTI results may represent possible remyelination within acute lesions and chronic axonal degeneration in NAWM. Evolution of gadolinium-enhancing lesions into T1 black holes is related more to the degree of initial injury than the degree of later recovery. These results support the use of DTI as a measure of tissue integrity for studies of neuroprotective therapies.

References

1. Fox RJ. Picturing multiple sclerosis: conventional and diffusion tensor imaging. Semin Neurol 2008;28:453–66
2. Basser PJ, Pierpaoli C. Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J Magn Reson 1996;111:209–19
3. Pierpaoli C, Basser PJ. Toward a quantitative assessment of diffusion anisotropy. Magn Reson Med 1996;36:893–906
4. Kim JH, Bulde MD, Liang HF, et al. Detecting axon damage in spinal cord from a mouse model of multiple sclerosis. Neurobiol Dis 2006;21:626–32
5. DeBoy CA, Zhang J, Dike S, et al. High-resolution diffusion tensor imaging of axonal damage in focal inflammatory and demyelinating lesions in rat spinal cord. Brain 2007;130:2199–210
6. Concha L, Gross DW, Wheatley BM, et al. Diffusion tensor imaging of time-dependent axonal and myelin degradation after corpus callosumotomy in epileptic patients. Neuroimage 2006;32:1090–99
7. Schmierer K, Wheeler-Kingshott CA, Bouly PA, et al. Diffusion tensor imaging of post mortem multiple sclerosis brain. Neuroimage 2007;35:467–77. Epidh 2006 Dec 16
8. Song SK, Sun SW, Ju WK, et al. Diffusion tensor imaging detects and differentiates axon and myelin degeneration in mouse optic nerve after retinal ischemia. Neuroimage 2003;26:1714–22
9. Song SK, Sun SW, Ramsbottom MJ, et al. Dysmyelination revealed through MRI as increased radial (but unchanged axial) diffusion of water. Neuroimage 2002;17:1429–36
10. Fox RJ, McColl RW, Lee JC, et al. A preliminary validation study of diffusion tensor imaging as a measure of functional brain injury. Arch Neurolog 2008;65:1179–84
11. Lowe MJ, Horenstein C, Hirsch JC, et al. Functional pathway-defined MRI diffusion measures reveal increased transverse diffusivity of water in multiple sclerosis. Neuroimage 2006;32:1127–33
12. Naismith RT, Xu J, Tutlam NT, et al. Disability in optic neuritis correlates with diffusion tensor-derived directional diffusivities. Neurology 2009;72:589–94
13. Cox RW. AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. Comput Biomed Res 1996;29:162–73
14. Smith SM, Jenkinson M, Woolrich MW, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004;23(suppl 1):S208–19
15. Prince JW, Barnard RO, Kwon EE, et al. Multiple sclerosis remyelination of nascent lesions. Ann Neurol 1993;33:157–31
16. Raine CS, Wu E. Multiple sclerosis: remyelination in acute lesions. J Neuro-pathol Exp Neurol 1993;52:199–204
17. Prince JW, Kwon EE, Cho ES, et al. Continual breakdown and regeneration of myelin in progressive multiple sclerosis plaques. Ann N Y Acad Sci 1984; 426:11–32
18. Song SK, Yoshino J, Le TQ, et al. Demyelination increases radial diffusivity in corpus callosum of mouse brain. Neuroimage 2005;26:132–40
19. Wang S, Wu EX, Tam CN, et al. Characterization of white matter injury in a hypoxic-ischemic neonatal rat model by diffusion tensor MRI. Stroke 2008;39:2348–53
20. Mac Donald CL, Dikranian K, Song SK, et al. Detection of traumatic axonal injury with diffusion tensor imaging in a mouse model of traumatic brain injury. Exp Neurol 2007;205:116–31
21. Kumar R, Gupta RK, Elderkin-Thompson V, et al. Voxel-based diffusion tensor magnetic resonance imaging evaluation of low-grade hepatic encephalopathy. *J Magn Reson Imaging* 2008;27:1061–68.

22. Kale RA, Gupta RK, Saraswat VA, et al. Demonstration of interstitial cerebral edema with diffusion tensor MR imaging in type C hepatic encephalopathy. *Hepatology* 2006;43:698–706.

23. Toh CH, Castillo M, Wong AM, et al. Differentiation between classic and atypical meningiomas with use of diffusion tensor imaging. *AJNR Am J Neuroradiol* 2008;29:1630–35.

24. Sundgren PC, Fan X, Weybright P, et al. Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast-enhancing lesions. *Magn Reson Imaging* 2006;24:1131–42.

25. van Walderveen MA, Kamphorst W, Scheltens P, et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. *Neurology* 1998;50:1282–88.

26. Bitsch A, Kuhlmann T, Stadelmann C, et al. A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions. *Ann Neurol* 2001;49:793–96.

27. Fisher E, Chang A, Fox RJ, et al. Imaging correlates of axonal swelling in chronic multiple sclerosis brains. *Ann Neurol* 2007;62:219–28.

28. Miller DH, Soon D, Fernando KT, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. *Neurology* 2007;68:1390–401.

29. Orea-Guevara C, Rovaris M, Iannucci G, et al. Progressive gray matter damage in patients with relapsing-remitting multiple sclerosis: a longitudinal diffusion tensor magnetic resonance imaging study. *Arch Neurol* 2005;62:578–84.

30. Agosta F, Absinta M, Sormani MP, et al. In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study. *Brain* 2007;130:2211–19.

31. Jones DK. The effect of gradient sampling schemes on measures derived from diffusion tensor MRI: a Monte Carlo study. *Magn Reson Med* 2004;51:807–15.

32. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. *New Engl J Med* 2003;348:15–23.

33. Rudick RA, Stewart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. *N Engl J Med* 2006;354:911–23.

34. Polman C, O’Connor P, Havrdova E, et al. Clinical results from AFFIRM: a randomized double-blind, placebo-controlled, multicenter trial to determine the efficacy and safety of natalizumab in patients with relapsing multiple sclerosis (MS). *Neurology* 2005;64(suppl 1):A146.

35. Dalton CM, Miszkell KA, Barker GJ, et al. Effect of natalizumab on conversion of gadolinium-enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. *J Neurol* 2004;251:407–13.

36. Broderick S, Piercy C, Steinman L, et al. Antibodies to CD44 and integrin alpha4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. *Proc Natl Acad Sci USA* 1999;96:8896–901.

37. Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. *Nature* 1992;356:63–66.

38. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? *Annu Rev Neurosci* 2008;31:247–69.

39. Imtilo J, Chitnis T, Khoury SJ. Insights into the molecular pathogenesis of progression in multiple sclerosis: potential implications for future therapies. *Arch Neurol* 2006;63:25–33.